Opdivo News & Analysis

Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue

Bristol Myers Squibb (BMY) reported Q1 adjusted earnings of $1.58 per share, exceeding analysts' expectations of $1.42, with revenue of $11.49 billion also surpassing the forecast of $10.9 billion. Eliquis, partnered with Pfizer, generated $4.14 billion in sales, an increase of 16% year-over-year. Sales from the growth portfolio rose 12% to $6.23 billion, while sales of Opdivo fell 5% to $2.15 billion. The company reaffirmed its 2026 revenue outlook of $46.0 billion to $47.5 billion and adjusted earnings of $6.05 to $6.35 per share.